According to the latest filings, corporate insiders at Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) have increased their position in the stock by 23.24% over the past 6 months. Insiders now own 17.53% of total outstanding shares.
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) stands -13.09% away from its 50-day simple moving average and also -8.52% away from the 200-day average. Recently, the equity stands -59.91% away from the 52-week high and 43.28% from the 52-week low. The RSI (Relative Strength Index), an indicator that shows price strength by comparing upward and downward close-to-close movements is 44.54.
Wall Street analysts on the sell-side covering shares of Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) have a mean recommendation of 2.00 on the shares. This is based on a numerical chart where each stock recommendation (Buy,Sell,Hold) is translated into a numerical equivalent. A low number indicates a Buy and a higher number a Sell. In terms of where analysts see the stock headed, they have a consensus price target of $7.00 on the shares.